Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
47,000
Eli Lilly and Co News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
markets
December 2025 US stock market outlook: Where we see investment opportunities
Heading into year-end, Santa Claus Rally or AI exhaustion?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,172.50 | 12.40 | 0.14% |
| CAC 40 | 8,148.89 | 79.72 | 0.99% |
| DAX 40 | 24,856.47 | 295.49 | 1.20% |
| Dow JONES (US) | 49,554.72 | 477.49 | 0.97% |
| FTSE 100 | 10,150.05 | 11.96 | 0.12% |
| HKSE | 26,629.96 | 44.90 | 0.17% |
| NASDAQ | 23,477.41 | 252.59 | 1.09% |
| Nikkei 225 | 53,688.89 | 914.25 | 1.73% |
| NZX 50 Index | 13,556.87 | 139.70 | 1.04% |
| S&P 500 | 6,929.11 | 53.49 | 0.78% |
| S&P/ASX 200 | 8,848.70 | 12.80 | 0.14% |
| SSE Composite Index | 4,122.58 | 5.64 | 0.14% |